Search ARM

Q2 2019 Report


This quarterly sector report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

Global Landscape

933+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

Financings

Q2 2019 Global Financings

Total Global Financings

$2.6 Billion

 38%

Decrease from Q2 2018

$4.8B Raised YTD
40% decrease YoY from H1 2018

Gene & Gene-modified
Cell Therapy

$2.2 Billion

 18%

Decrease from Q2 2018

$4.3B Raised YTD
26% decrease YoY from H1 2018

Cell Therapy

$691 Million

 69%

Decrease from Q2 2018

$1.5B Raised YTD
64% decrease YoY from H1 2018

Tissue Engineering

$53 Million

 88%

Decrease from Q2 2018

$67M Raised YTD
91% decrease YoY from H1 2018

Total Global Financings by Type

1,069

Clinical trials underway
worldwide by the end of Q2 2019

PH. 1

358

PH. 2

617

PH. 3

94

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

End of Q2 2019

Gene Therapy
Gene-Modified
Cell Therapy
Cell Therapy
Tissue Engineering

Clinical Trials by Indication: Q2 2019